Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stentys starts stent study

This article was originally published in Clinica

Executive Summary

Stentys has enrolled the final patient in its APPOSITION II clinical study, a randomised trial comparing the Stentys self-expanding stent with a conventional balloon-expandable stent in patients with acute myocardial infarction (AMI). The study results will be announced in September. Stentys, which is based in Princeton, New Jersey and Paris, France, CE marked the device for sale in Europe for the treatment of acute coronary syndrome in March (www.clinica.co.uk, 8 March 2010). AMI affects 100,000 people every year in France and 900,000 people in the US.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT095153

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel